Effect Of Indobufen On Platelet Aggregation And Coagulation Mechanism In Elderly Patients With Coronary Heart Disease

Objective: To compare the clinical efficacy and safety of indobufen and aspirin in elderly patients with coronary heart disease.Methods: 50 elderly patients with coronary heart disease were randomly divided into the indobufen treatment group and the aspirin treatment group.The indobufen treatment group received indobufen(100 mg 2/day)for 2 weeks.The aspirin treatment group Aspirin(100 mg 1/day)was given for 2 weeks.Results:(1)After treatment with indobufen,ADP platelet aggregation rate and arachidonic acid aggregation rate were significantly lower in elderly patients with coronary heart disease(P<0.05);The international normalized ratio(INR),prothrombin time(PT),activated partial thromboplastin time(APTT)and thrombin time(TT)of prothrombin were higher than those before treatment(P<0.05),while the fibrinogen content(FIB)was lower than that before treatment(P<0.05).(2)After treatment with aspirin,ADP platelet aggregation rate and arachidonic acid aggregation rate were significantly lower in elderly patients with coronary heart disease(P<0.05);PT was higher than before treatment(P<0.05),and INR,FIB,and TT were lower than before treatment(P<0.05),but APTT was no statistical change before and after treatmen(P>0.05).(3)No adverse reactions occurred in the indobufen treatment group,and the incidence of adverse reactions associated with indobufen was 0%(0/25).There were 2 cases of adverse reactions in the aspirin-treated group,1 case showed gastrointestinal discomfort,and the symptoms improved after omeprazole was given.The other 1 case showed mild bleeding,ie,a small amount of bleeding spots were visible on the hands and skin,no special treatment,and aspirin The incidence of related adverse reactions was 8%(2/25).No serious adverse reactions occurred during the entire treatment period.Conclusion: Both indobufen and aspirin can significantly reduce the platelet aggregation rate.The indobufen treatment group is more effective in reducing the arachidonic acid aggregation rate in elderly patients with coronary heart disease than in the aspirin treatment group.The drug has different effects on the reduction of ADP platelet aggregation rate in elderly patients with coronary heart disease.In addition,indobufen can exert anticoagulant effects to a certain extent.At the same time,indobufen has a higher safety than aspirin in elderly patients with coronary heart disease.